Aiko Biotechnology, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Aiko Biotechnology, Inc. - overview
Established
2006
Location
Portland, ME, US
Primary Industry
Pharmaceuticals
About
Aiko Biotechnology, Inc. focuses on delivering innovative solutions to enhance operational efficiency for diverse businesses, specializing in advanced software platforms that streamline processes and optimize resource allocation. Founded in 2006 and headquartered in Portland, US, Aiko Biotechnology, Inc. develops software aimed at improving operational efficiency.
The company has engaged in one deal, raising USD 0. 85 mn in funding on December 3, 2009. Aiko Biotechnology, Inc. offers a suite of innovative software solutions designed to enhance operational efficiency across various sectors.
Their core products include advanced platforms that streamline processes, improve data management, and optimize resource allocation. These solutions cater to industries such as manufacturing, logistics, and retail, targeting challenges like inventory management and supply chain optimization. The offerings are tailored for a diverse clientele, from mid-sized enterprises to Fortune 500 companies, and have been deployed in key markets across North America, Europe, and Asia-Pacific. The company's revenue model is based on subscription-based services and direct sales of its software products.
Clients usually enter into annual subscription agreements providing access to software and regular updates. Tiered pricing plans cater to different service levels and user capacities, accommodating both B2B partnerships and direct-to-consumer sales. Flagship products contribute to the revenue stream by developing a loyal customer base, ensuring consistent financial performance. Aiko Biotechnology, Inc.
plans to utilize the USD 0. 85 mn raised in funding in December 2009 to enhance its product offerings and expand into new markets. The company is focused on launching new software solutions tailored for specific industries by mid-2024. Additionally, Aiko aims to penetrate emerging markets in Asia-Pacific and Europe, targeting a launch by the end of 2025.
These initiatives are designed to support the company’s strategic growth and operational scalability.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceuticals
Website
www.aikobiotech.com
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.